87 results about "Respiratory infection" patented technology

The invention relates to the technical field of biomedicine, in particular to a primer probe combination for broad-spectrum screening of common respiratory pathogens and application of the primer probe combination. Through screening and optimization, the respiratory pathogen nucleic acid detection primer probe combination for broad-spectrum screening of common acute respiratory infection and community-acquired pneumonia is obtained; the primer probe combination covers 18 respiratory tract pathogens, has the advantages of high accuracy, good specificity, strong anti-interference capability, good inclusiveness, high sensitivity, hyperjoint detection and the like, can realize parallel detection of 20 targets in cooperation with totally-closed single-tube PCR amplification, greatly improves early diagnosis of respiratory tract diseases with complex pathogen structures, and has wide application prospects. The method has very important significance on prevention, control and treatment of infectious diseases.

The present invention relates to TLR2 agonist compounds and their compositions, and the use of such compounds and compositions in the prevention and / or treatment of respiratory infections, or diseases or conditions associated with viral or bacterial infections.

The invention relates to the technical field of medical protection tools, and discloses a respiratory tract infection-free throat swab collecting device which comprises a transparent mask, a shell is arranged on the outer side of the transparent mask, a filtering mechanism is arranged on the transparent mask, a collecting swab and a push block are arranged in the shell, a round plate is arranged on the outer side of the push block, and a through hole is formed in the round plate. And cutting mechanisms are further arranged in the shell, the cutting mechanisms are distributed on the two sides of the shell, and each cutting mechanism comprises a sliding block, a connecting assembly, a pushing assembly and a cutting knife. The effect of automatically cutting off the collecting swab after collecting is completed is achieved, so that the problem that after collecting of the collecting swab is completed, the collecting swab needs to be manually broken off is avoided, a filtering mechanism can filter breathing air of a patient and airflow generated during sneezing and coughing, and therefore the collecting swab is prevented from being manually broken off. And the effect that the collecting swab is moved out of the oral cavity or the nasal cavity of the patient through one key can be achieved.

Composition and methods for treatment or prevention of a respiratory infection in a mammal, including a viral infection, like a coronavirus such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or variants thereof. The compositions and methods include a therapeutically effective amount of about a 1% solution of N-chlorotaurine in water. The methods include administering N-chlorotaurine by nasal spray to the nostrils, by oral spray to the throat, and by nebulizer to the lungs.

The present invention relates to TLR2 agonist compounds and their compositions, and the use of such compounds and compositions in the prevention and / or treatment of respiratory infections, or diseases or conditions associated with viral or bacterial infections.

The invention relates to the technical field of acute respiratory infection prediction, in particular to a model training method and system for acute respiratory infection prediction and a medium. The method comprises the following steps: carrying out original data collection and time window division on a target patient to obtain time window data; performing biological rhythm feature extraction according to the time window data to obtain biological rhythm feature data; performing window feature screening on the biological rhythm feature data to obtain important biological rhythm time window feature data; performing time sequence arrangement on the important biological rhythm time window feature data to obtain patient multi-scale time sequence feature data; and constructing a VAE model according to the multi-scale time sequence feature data of the patient to obtain the VAE model. According to the method, the problem that an existing model is insufficient in consideration of individual differences and dynamic changes is solved, and more accurate and more personalized acute respiratory infection risk prediction is achieved.

The present invention relates to an antiviral application of nucleoside analogs. Specifically, the present invention relates to uses of nucleoside analogs and a pharmaceutical composition thereof as: (a) inhibitors for inhibiting the replication of coronaviruses, influenza viruses, respiratory syncytial viruses, flaviviridae viruses, filoviridae viruses and / or porcine epidemic diarrhea virus (PEDV); and / or (b) medicines for treating and / or preventing and mitigating diseases caused by coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and / or porcine epidemic diarrhea virus (PEDV) infections. The nucleoside analogs according to the invention may treat and / or prevent and mitigate respiratory infection, pneumonia (COVID-19) and other related diseases caused by 2019 novel coronavirus infection.

The invention relates to the technical field of biology, in particular to a primer probe combination product for respiratory tract infection detection. A plurality of specific primers and self-quenching probes are integrated in a single reaction system; simultaneous, rapid and rapid detection on 15 respiratory pathogens (including influenza A virus, influenza B virus, respiratory syncytial virus, severe acute respiratory syndrome coronavirus 2, mycoplasma pneumoniae, parainfluenza virus, rhinovirus, enterovirus, coronavirus, adenovirus, metapneumovirus, bordetella pertussis, bocavirus, chlamydia pneumoniae and chlamydia psittaci) is realized. The detection is accurate.

The invention belongs to the technical field of medicinal and edible health-care food, and particularly relates to a traditional Chinese medicine composition for tonifying qi and enhancing immunity for children as well as a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by mass: 5 to 10 parts of radix codonopsis, 10 to 20 parts of radix fici simplicissimae, 10 to 20 parts of poria cocos, 10 to 20 parts of malt and 10 to 20 parts of fructus mume. Through ingenious compatibility, the monarch drug codonopsis pilosula and the ministerial drug radix fici simplicissimae are matched with each other to tonify spleen, tonify qi and regulate the immune function of a body, meanwhile, poria cocos, malt and smoked plum are matched to tonify spleen, promote digestion and nourish yin, moistening and dryness are matched in the whole formula, and the traditional Chinese medicine has the effects of tonifying spleen, tonifying lung, nourishing without obstructing spleen and stomach and warming without dryness to tonify qi and increase immunity. Clinical research finds that the traditional Chinese medicine composition for tonifying qi and enhancing immunity for children can obviously improve clinical symptoms of children patients with recurrent respiratory tract infection.

This invention relates to the use of compounds of formula (I), or pharmaceutically acceptable salts or solvates thereof, in the treatment or prevention of mycobacterial infections, wherein: one of R2 and R3 is H, and the other is (CR) a R b ) n Y; Y is selected from CO2R c CN and CONR e R f R4 is selected from H, halogens, CN, alkyl and alkoxy groups; R6 is selected from H, F, Br, I, COOH, CN, COR. d CO2R d Alkyl, haloalkyl, alkoxy, haloalkoxy, nitro, OH, SR d SOR d SO2R d SO2NR d R d NHSO2R d aryl and heteroaryl groups, wherein the aryl or heteroaryl group is optionally substituted by one or more substituents selected from alkyl, alkoxy, halogen, haloalkyl, and haloalkoxy groups; R7 is selected from H, halogen, alkyl, and alkoxy groups; R9 is selected from H, COR... d Alkyl, haloalkyl, aryl, CO-aryl, CO-haloaryl, aralkyl and haloaralkyl; R1, R5 and R8 are H; each R a R b R c R d R e and R f The compounds are independently selected from H, alkyl, and haloalkyl groups; n is 1 to 6. Other aspects of the invention relate to subgroups of compounds of formula (Ia), pharmaceutical compositions comprising such subgroups, and their use in the treatment or prevention of mycobacterial infections.

A compound or a pharmaceutically acceptable salt thereof for use in a method of treatment of a disease or condition in which signalling through the PI3Kδ pathway is pathologically implicated in patients, for example cancer and inflammatory or autoimmune diseases. The compound is provided at a specified dose and has been found to have a favourable safety profile in humans, in particular with regard to hepatotoxicity, diarrhoea / colitis, respiratory infections, and hematologic toxicities.

Provided herein are methods of treating a trauma patient, the method including: (a) administering a HDAC inhibitor to the trauma patient; and (b) administering a GRK2 inhibitor to the trauma patient, wherein the treatment prevents, reduces, or ameliorates the risk of an infection occurring after a traumatic event. In some cases, the infection is a respiratory infection, such as pneumonia. The HDAC inhibitor and / or the GRK2 inhibitor can be administered to the patient before, after, or before and after the traumatic event.

The invention relates to an application of a composition of seven probiotics in preparation of an anti-influenza virus probiotic agent. The bacterial strains in the probiotic composition comprise a combination of a streptococcus thermophilus CT-02 bacterial strain, a bifidobacterium animalis subsp. Lactis C-2 bacterial strain, a bifidobacterium longum subsp. Infantis C-3 bacterial strain, a lactobacillus delbrueckii subsp. Bulgaricus CB-01 bacterial strain, a lactobacillus acidophilus CL-01 bacterial strain, a lactobacillus paracasei CL-02 bacterial strain and a lactobacillus rhamnosus CL-03 bacterial strain. New application of the probiotic composition is developed, a research basis is provided for wide application of the probiotic composition, meanwhile, a brand-new strategy for preventing, relieving or treating influenza is also developed, it is found that the probiotic composition has a very remarkable effect in the aspect of relieving related symptoms caused by the influenza, and the probiotic composition has a good application prospect. Specifically, related symptoms such as respiratory system infection, body temperature imbalance, weight loss and vision weakening caused by influenza virus infection are obviously improved.

The invention belongs to the field of biology, and discloses a multiple primer probe set and application thereof. Wherein the multiple primer probe group comprises corresponding primers and probes for detecting seven respiratory tract infection pathogens including canine distemper virus, canine adenovirus type 2, canine parainfluenza virus, canine influenza virus, canine respiratory tract coronavirus, new coronavirus and bordetella bronchiseptica, and the invention also discloses a kit for detecting the respiratory tract infection pathogens including canine distemper virus, canine adenovirus type 2, canine parainfluenza virus, canine influenza virus, canine respiratory tract coronavirus, new coronavirus and bordetella bronchiseptica. The kit is composed of a qPCR reaction solution A1, a qPCR reaction solution A2, an enzyme system mixture, a positive quality control product and a negative quality control product. In the application, the multiple qPCR kit is simple to operate and short in consumed time, the seven different common respiratory tract infection pathogens can be detected at one time through a two-tube reaction system, and the lowest detectable concentration of the seven respiratory tract infection pathogens is 0.1 copies / uL, so that the kit is suitable for clinical rapid detection of the respiratory tract pathogens; and timely and correct treatment aiming at infected pathogens is facilitated.

This application provides a wearable device and a method for evaluating a respiratory tract infection. The wearable device may include at least one first sensor, configured to obtain an audio signal of a user; at least one second sensor, configured to obtain a physiological parameter signal of the user, wherein the at least one second sensor comprises a photoplethysmography (PPG) sensor, the PPG sensor is configured to obtain a PPG signal of the user; and at least one processor, configured to: obtain a first respiratory rate of the user based on the PPG signal, and obtain a respiratory tract infection evaluation report of the user based on the audio signal and the first respiratory rate.

The invention relates to the field of atomization drug delivery, in particular to a respiratory tract infection drug delivery device which comprises a heating cylinder, two sets of shielding plates are fixedly connected to the inner side wall face of the heating cylinder and located on the upper side edge and the lower side edge, and air holes are formed in the outer side surfaces of the two sets of shielding plates and located on the two opposite side edges correspondingly. A limiting sleeve is fixedly installed on the outer side surface of the heating cylinder and located between the two shielding plates, and a supporting cylinder is arranged on the outer side surface of the heating cylinder and located at the symmetrical position of the limiting sleeve. When a medicine mist cluster passes through air holes in the outer side surface of a baffle plate and rotates on the surface of a threaded rod in cooperation with a screw cap, the threaded rod and a heating rod horizontally move towards one side under the limitation of a limiting sleeve and a supporting cylinder, and the heating rod moves out from the interior of the limiting sleeve, and when the medicine mist cluster passes through the air holes in the outer side surface of the baffle plate to flow, the medicine mist cluster flows out. And the medicine mist cluster is in contact with the surface of the heating rod.

An artificial intelligence-based system and method for scalable screening of individuals for respiratory infection, such as COVID-19. The system is trained to distinguish distinct latent features of cough sounds produced by a COVID-19 infected person from cough sounds produced by patients suffering from any other respiratory infection or involuntary cough sounds produced by a healthy person. Cough sound samples from individuals can be remotely collected and evaluated by the system for likelihood of the COVID-19 infection. Additionally, images of affected body parts, biomarkers, metadata, and other respiratory sound samples can also be used for screening.

The invention discloses a children respiratory disease early warning method based on atmospheric environment monitoring and a deep learning model. The children respiratory disease early warning method comprises the following steps: step S1, acquiring past atmospheric environment monitoring and children respiratory infection admission data of a certain region; s2, an LSTM model and a DLNM model are constructed and trained; s3, predicting atmospheric environment data of a next time sequence based on the LSTM model; s4, inputting the predicted atmospheric environment data of the next time sequence into the DLNM model; and S5, outputting a prediction result of the children respiratory tract infection epidemic condition of the next time sequence. According to the invention, through combination of the long short-term memory network (LSTM) and the distributed hysteresis nonlinear model (DLNM), accurate prediction of the number of children respiratory disease patients is realized.

The invention relates to a medicament containing gold for use in the prevention or therapy of chronic obstructive pulmonary disease (COPD), preferably with accompanying respiratory tract infection, wherein the medicament is administered by inhalation. The invention further relates to a process for preparing a ready-to-administer solution of a medicament containing gold.

The utility model provides a novel artificial airway which comprises an artificial airway body, the artificial airway body comprises a first end and a second end which are communicated with each other, at least two air bags arranged at intervals in the axial direction of the artificial airway body are arranged at the position, close to the second end, of the outer side wall of the artificial airway body, and the air bags are connected with a first catheter; the first catheter extends along the extending direction of the artificial airway; the inflating and deflating device body is connected to the end, away from the air bag, of the first catheter, and the inflating and deflating device body is used for inflating and deflating the air bag; wherein a suction pump is arranged in the inflation and deflation device body, the suction end of the suction pump is connected with a second guide pipe, and the second guide pipe extends to the position of the air bag. According to the scheme, the air bag is decompressed and inflated at regular time through the inflation and deflation device body, and meanwhile retentate deposited near the air bag is removed at regular time through the suction pump. Ischemic injury and even necrosis of tracheal mucosa due to compression are avoided, and respiratory tract infection of a patient due to long-time accumulation of retentate is avoided.

The present application relates to the field of biochemistry, and discloses a multiple primer set and a kit for detecting pathogens of acute infection of the lower respiratory tract, including primer pairs for detecting Mycoplasma pneumoniae, primer pairs for detecting Chlamydia pneumoniae, primer pairs for detecting Staphylococcus aureus, primer pairs for detecting Haemophilus influenzae, primer pairs for detecting Streptococcus pneumoniae, and primer pairs for detecting Klebsiella pneumoniae. The multiple primer set for detecting pathogens of acute infection of the lower respiratory tract of the present application can realize simultaneous amplification and detection of 6 targets, and is suitable for screening of clinical cases of acute lower respiratory tract infection.

The present disclosure relates to methods for reducing infections, particularly respiratory viral infections, for example in subjects with COPD, the methods comprising the use of IL-33 antagonists, particularly oxIL-33 antagonists.

Provided herein are pharmaceutical compositions, therapeutic combinations, devices and methods for treating, ameliorating, reversing, causing the remission of, and / or preventing (acting as a prophylaxis, or preventing the initiation of) an inflammatory bowel disorder (IBD) or inflammatory bowel disease (IBD), Ulcerative Colitis; Crohn's disease; J-pouch; fistulising Crohn's disease; a Colitis which can be microscopic, lymphocytic or collagenous; an eosinophilic colitis; indeterminate colitis; idiopathic colitis; diverticulosis and diverticulitis; relapsing diverticulitis; constipation associated inflammatory bowel disease and / or small intestinal bacterial overgrowth; Irritable Bowel Syndrome (IBS) with or without diarrhoea, constipation or pain predominant IBS; periodontitis; rheumatoid arthritis; respiratory infections, appendicitis, vascular disorders such as thrombophlebitis; bacteremia; osteomyelitis; septic shock; Alzheimer's disease; Lemierre syndrome (postanginal sepsis); colonic polyps or adenomas (optionally hyperplastic, adenomatous or serrated adenomas) or preventing the growth of colonic polyps or adenomas, bowl cancer, or metastases (optionally preventing the initiation or promotion of bowl cancer or metastasis); pharyngitis; otitis; sinusitis; and any disease, symptom or condition caused or exacerbated by a Fusobacteria (optionally, a F. nucleatum or F. varium) infection. In alternative embodiments, pharmaceutical compositions comprise rifaximin alone or in combination with other antibiotics or drugs.

The present invention relates to a drug aerosol supply apparatus for a respirator, and the objective of the present invention is to prevent secondary respiratory infection due to condensation water. The drug aerosol supply apparatus according to the present invention comprises a T tube, a drug particulate generation unit and a heater. The T tube includes a straight tube having a first end portion to which air provided from a respirator is provided and having a second end portion connected to a mask or a mouthpiece, and a branch tube attached to the straight tube so as to allow communication with the straight tube. The drug particulate generation unit is installed at the branch tube and sprays a drug in a particulate state. The heater for heats the T tube.

The present disclosure describes a method of treating a respiratory condition, wherein the respiratory condition is a respiratory enterovirus infection, an upper respiratory infection, a common cold, or a combination thereof, in a human subject with COPD which includes administering to the subject a therapeutically effective amount of vapendavir or a pharmaceutically acceptable salt thereof, thereby treating the respiratory condition in the subject. Pharmaceutical formulations of vapendavir and pharmaceutically acceptable salts thereof are also disclosed.

The invention relates to feed collection and storage, and discloses a dust screening mechanism and a cattle branch feed collection and storage device and method.The dust screening mechanism comprises a collection and storage tank, a dust screening box is arranged at the top of the collection and storage tank, a screening plate with dust holes is installed in the dust screening box, and the screening plate divides a box body into a dust collection chamber and a feeding chamber; a feeding port and a discharging port are formed in the upper end and the lower end of the feeding chamber respectively, the discharging port is communicated with the interior of the storage tank, the screening plate inclines downwards towards the discharging port, a material blocking plate which inclines downwards towards the screening plate is arranged at the feeding port, and a material passing channel is formed between the end, facing the screening plate, of the material blocking plate and the plate face of the screening plate. By arranging the feed collecting and storing device capable of screening the feed dust, the feed dust can be separated from pellet feed in the collecting and storing process, so that the effect of reducing the feed dust is achieved, and then the risk of respiratory tract infection is further reduced.

Disclosed herein are methods for subtyping patients with a respiratory infection (e.g., community acquired pneuomonia or severe acute respiratory infection) to identify likely responders to corticosteroid therapy. The methods involve analyzing values of a plurality of biomarkers, examples of which include a first biomarker selected from procalcitonin, IL-6, and TREM-1, and a second biomarker selected from Pentraxin-3, MIP-3α, IL-1ra, IL-8, and NGAL. The methods enable personalized treatment decisions for patients with respiratory infections, potentially improving patient outcomes by targeting corticosteroid therapy to those most likely to benefit while avoiding harm to non-responders.

The present invention discloses a traditional Chinese medicine composition with the effects of replenishing qi and drying dampness and its application. The present invention provides a new application of a known traditional Chinese medicine composition for blocking the carcinogenic transformation of colitis in the preparation of a drug for treating cough. The present invention also obtains a new traditional Chinese medicine composition by improvement on the basis of this formula, which not only has a cough-relieving effect, but also has a good therapeutic effect on the sticky phlegm accompanied by cough caused by respiratory tract infection, chronic obstructive pulmonary disease, pharyngitis and bronchitis.

This utility model discloses a water feeding device for squab farming, relating to the technical field of water feeding devices. By incorporating a filtration mechanism and a support component, the support component allows the water feeding device to be positioned away from the ground, while the filtration mechanism continuously filters the water inside the feeding bowl, ensuring its cleanliness. This solves the problem of traditional squab water feeding methods, which often use simple troughs or bowls placed directly on the floor of the pigeon coop or in fixed locations. However, this primitive water feeding method has many drawbacks. Firstly, the water quality is easily polluted. During the drinking process, squabs' feathers, droppings, and feed residue easily fall into the water, causing rapid water deterioration and the proliferation of bacteria and microorganisms. Squabs drinking contaminated water are prone to various diseases, such as intestinal and respiratory infections, which not only affect their growth and development but also increase the farmer's medication costs and farming risks, and may even lead to squab death and economic losses.

The present invention relates to the field of acute respiratory infection prediction technology, and in particular to a model training method, system and medium for acute respiratory infection prediction. The method comprises the following steps: collecting raw data of target patients and dividing time windows to obtain time window data; extracting biorhythm features based on the time window data to obtain biorhythm feature data; performing window feature screening on the biorhythm feature data to obtain important biorhythm time window feature data; arranging the important biorhythm time window feature data in time sequence to obtain multi-scale time series feature data of patients; constructing a VAE model based on the multi-scale time series feature data of patients to obtain a VAE model. The present invention achieves a more accurate and personalized prediction of the risk of acute respiratory infection by solving the problem that the existing models do not take into account individual differences and dynamic changes.